Shopping Cart
- Remove All
Your shopping cart is currently empty
Lintitript
Catalog No. T15759Cas No. 136381-85-6
Alias SR 27897
Lintitript (SR 27897) is a selective CCK1 antagonist with an EC50 of 6 nM for CCK1 and 200 nM for CCK2, and a Ki value of 0.2 nM for CCK1.
Lintitript
Catalog No. T15759Alias SR 27897Cas No. 136381-85-6
Lintitript (SR 27897) is a selective CCK1 antagonist with an EC50 of 6 nM for CCK1 and 200 nM for CCK2, and a Ki value of 0.2 nM for CCK1.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $117 | In Stock | |
| 2 mg | $160 | In Stock | |
| 5 mg | $247 | In Stock | |
| 10 mg | $370 | In Stock | |
| 25 mg | $591 | In Stock | |
| 50 mg | $798 | In Stock | |
| 100 mg | $1,070 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $273 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Lintitript"
N-Cbz-DL-tryptophan
T934313058-16-7
N-Cbz-DL-tryptophan is a cholecystokinin receptor antagonist, abolished the response of the isolated heart to CCK-8.
- $35
Size
QTY
Proglumide
T10526620-60-6
Proglumide (Binoside) is a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. Proglumide is a drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
- $33
Size
QTY
PHA-767491
Cited
PHA767491, PHA 767491, CAY10572
T6206845714-00-3
PHA-767491 (CAY10572) is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.
- $30
Size
QTY
CitedItriglumide
CR-2945, CR2945, CR 2945
T27640201605-51-8In house
Itriglumide (CR-2945) is a cholecystokinin (CCK)-2 receptor antagonist with antisecretory and antiulcerogenic properties.
- $293
Size
QTY
GV150013
GV-150013, GV 150013
T27503167355-22-8In house
GV150013 is an antagonist of cholecystokinin-2 (CCK2) receptor.
- $197
Size
QTY
GV-150013X
(S)-1-(1-(adamantan-1-ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-3-phenylurea
T27503L151386-96-8In house
GV-150013X ((S)-1-(1-(adamantan-1-ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-3-phenylurea) is a potent CCKB antiagonist, pKi= 9.02.
- $197
Size
QTY
Spiroglumide
CR-2194
T68016137795-35-8In house
Spiroglumide, a CCKB-gastrin antagonist that inhibits dose-dependent pentagastrin-induced acid hypersecretion with an ID50 of 20.1 (8.67-46.4) mg / kg, could be used to explore the physiological role of gastrin in the regulation of human gastric acid secretion.
- $158
Size
QTY
XL413 hydrochloride
XL413, BMS-863233 Hydrochloride, BMS-863233
T67352062200-97-7
XL413 hydrochloride (BMS-863233 Hydrochloride) is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC 50 of 3.4 nM. XL413 hydrochloride also exhibits potent effect with IC 50 s of 215, 42 nM on CK2, PIM1, respectively, and an EC 50 of 118 nM on pMCM.
- $48
Size
QTY
A-65186
A65186, A 65186
T26483119295-94-2In house
A-65186 is an A-type glutamatergic cholecystokinin (CCK) antagonist used to study inflammation and gastrointestinal tract injury.
- $293
Size
QTY
Loxiglumide
CR-1505
T2312107097-80-3
Loxiglumide (CR-1505) is an antagonist of cholecystokinin (CCK-1) receptor.
- $34
Size
QTY
CCK Octapeptide, non-sulfated acetate
CCK Octapeptide, non-sulfated acetate(25679-24-7 Free base)
TP2204L
CCK Octapeptide, non-sulfated acetate is a synthetic desulfated peptide of cholecystokinin.
- $131
Size
QTY
Gastrin I (human) acetate
Little gastrin I acetate, Gastrin-17 acetate, Gastrin I (human) acetate(10047-33-3 free base)
TP2030L1
Gastrin I (human) acetate (Gastrin-17 acetate) is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.
- $73
Size
QTY
Select Batch
Purity:98.48%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Lintitript (SR 27897) is a selective CCK1 antagonist with an EC50 of 6 nM for CCK1 and 200 nM for CCK2, and a Ki value of 0.2 nM for CCK1. |
| Targets&IC50 | CCK1 receptor:(ki)0.2 nM, CCK1:(EC50)6 nM |
| In vitro | Lintitript inhibited the CCK 2 site in guinea pig cortex with an IC2 of 479 nM. lintitript (0.5 nM) increased the dissociation constant of CCK on CCKA receptors with Kds between 1.8 and 7.2 nM without altering the maximum number of receptors. lintitript antagonized CCK-stimulated isolated rat pancreatic follicles in (amylase release and CCK-induced gallbladder contraction in guinea pigs with pA2s of 7.50 and 9.57). lintitript inhibited the binding of [125I]CCK to the rat pancreatic CCK1 receptor site with IC50 of 0.58 nM in a concentration-dependent manner[1]. |
| In vivo | Lintitript (1 mg/kg, i.v.) completely reversed CCK-induced amylase secretion. lintitript inhibited CCK-induced gastric and gallbladder emptying in mice with ED50s of 3 μg/kg and 72 μg/kg. lintitript (p.o.) was active in the gallbladder emptying protocol of egg yolk-induced endogenous CCK release, with an ED50 of 27 μg/kg [1]. |
| Alias | SR 27897 |
| Molecular Weight | 411.86 |
| Formula | C20H14ClN3O3S |
| Cas No. | 136381-85-6 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (218.5 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Lintitript | purchase Lintitript | Lintitript cost | order Lintitript | Lintitript chemical structure | Lintitript in vivo | Lintitript in vitro | Lintitript formula | Lintitript molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.